Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006

Human Vaccines

Volumn 3, Issue 5, 2007, Pages 196-204

  McNicholas, Anne ^a,h,i   Galloway, Yvonne ^a,h   Stehr Green, Paul ^a,b,h   Reid, Stewart ^a,c,h,i   Radke, Sarah ^a,h   Sexton, Kerry ^a,h   Kieft, Charlotte ^a,h   Macdonald, Claire ^a,h   Neutze, Jocelyn ^d,j   Drake, Ross ^e,j   Isaac, Dorothy ^d   O'Donnell, Mary ^e   Tatley, Michael ^f,i   Oster, Philipp ^g   O'Hallahan, Jane ^a,i  

^a MINISTRY OF HEALTH   (New Zealand)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Ropata Medical Centre   (New Zealand)

^d MIDDLEMORE HOSPITAL   (New Zealand)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f UNIVERSITY OF OTAGO   (New Zealand)

^g NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^h Data Management Group   (United States)

ⁱ Mortality Review Group   (New Zealand)

^j Clinical Review Committee ^*

more..

Author keywords

AEFI; Group B meningococcal vaccine; Outer membrane vesicle; Post marketing surveillance; Vaccine safety

Indexed keywords

MENINGOCOCCUS VACCINE;

ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BRAIN DISEASE; BRONCHOSPASM; DRUG MONITORING; DRUG SAFETY; FACE EDEMA; FEBRILE CONVULSION; FEVER; FLACCID PARALYSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPOTONIC HYPORESPONSIVE EPISODE; IMMUNOGENICITY; INJECTION SITE REACTION; IRRITABILITY; MUSCULOSKELETAL DISEASE; NEW ZEALAND; PERIORBITAL EDEMA; PETECHIA; POSTMARKETING SURVEILLANCE; PURPURIC RASH; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SYNCOPE; THROMBOCYTOPENIA; URTICARIA;

EID: 35348995008     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.5.4458     Document Type: Article

References (59)

1. Sexton K, Lennon D, Oster P, Crengle S, Martin D, Mulholland K, Percival T, Reid S, Stewart J, O'Hallahan J. The New Zealand Meningococcal Vaccine Strategy: A tailor-made vaccine to combat a devastating epidemic. N Z Med J 2004; 117(1200), (URL:http://www.nzma.org.nz/journal/117-1200/1015).
2. Holst J, Feiring B, Fuglesang J, Hoiby E, Nokleby H, Aaberge I, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21:734-7.
3. Sierra G, Campa H, Varcacel N, Garcia I, Izquierdo P, Sotolongo P, Casanueva G, Rico C, Rodriguez C, Terry M. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14:195-210.
4. Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W, Moran E, Hankins W, Gilly J, Mays J. The Chilean National Committee for Meningococcal Disease: Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 1995; 13:821-9.
5. Milagres L, Ramos S, Sacchi C, Melles C, Vieira V, Sato H, Brito G, Moraes J, Frasch C. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy. Infect Immun 1994; 62:4419-24.
6. Tappero J, Lagos R, Ballesteros A, Plikaytis B, Williams D, Dykes J, Gheesling L, Carlone G, Hoiby E, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman J, Perkins B. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomised control trial in Chile. JAMA 1999; 281:1520-7.
7. Perkins B, Jonsdottir K, Briem H, Griffiths E, Plikaytis B, Hoiby E, Rosenqvist E, Holst J, Nokleby H, Sotolongo F, Sierra G, Campa H, Carlone G, Williams D, Dykes J, Kapczynski D, Tikhomirov E, Wenger J, Broome C. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998; 177:683-91.
8. Holst J, Feiring B, Naess L, Norheim G, Kristiansen P, Hoiby E, Bryn K, Oster P, Costantino P, Taha M, Alonso J, Caugant D, Wedege E, Aaberge I, Rappuoli R, Rosenqvist E. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2202-5.
9. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB™: A safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23:2191-6.
10. Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nokleby H, Rosenqvist E, White K, Reid S, Mulholland K, Wakefield M, Martin D. Safety and immunogenicity of a New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control. Vaccine 2006; 24:1395-400.
11. Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O'Hallahan J, Oster P, Mulholland K, Martin D. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007; 26:345-50.
12. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a s train-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007; 25:3075-9.
13. Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 2007; 25:3080-4.
14. Aavitsland P, Bjune G, Aasen S, Halvoren S. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991. NIPH Ann 1991; 14:133-4.
15. Bjune G, Hoiby E, Gronnesby J, Arnesen O, Fredriksen J, Halstensen A, Holten E, Lindbak A, Nokleby H, Rosenqvist E, Solberg L, Closs O, Eng J, Froholm L, Lystad A, Bakketeig L, Hareide B. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-6.
16. O'Hallahan J, Lennon D, Oster P, Lane R, Reid S, Mulholland K, Stewart J, Penney L, Percival T, Martin D. From secondary prevention to primary prevention: A unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 2005; 23:2197-201.
17. Ministry of Health. Immunization Handbook 2006. Wellington: Ministry of Health, 2006.
18. Mansoor O, Pillans P. Vaccine adverse events reported in New Zealand 1990-95. N Z Med J 1997; 110:270-2.
19. Isaacs D, Lawrence G, Boyd I, Ronaldson K, McEwen J. Reporting of adverse events following immunization in Australia. J Paediatr Child Health 2005; 41:163-6.
20. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995; 85:1706-9.
21. Scheifele D, Halperin S, Members of IMPACT. Immunization monitoring program, active: A model of active surveillance of vaccine safety. Semin Pediatr Infect Dis 2003; 14:213-9.
22. Bonhoeffer J, Menkes J, Gold M, de Souza-Brito G, Fisher M, Halsey N, Vermeer P. The Brighton Collaboration Seizure Working Group. Generalized convulsive seizure as an adverse event following immunization: Case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004; 22:557-62.
23. Barlow W, Davis R, Glasser J, Rhodes P, Thompson R, Mullooly J, Black S, Shinefield H, Ward J, Marcy S, DeStefano F, Chen R. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New Eng J Med 2001; 345:656-61.
24. Davis R, Barlow W. Placing the risk of seizures with pediatric vaccines in a clinical context. Pediatr Drugs 2003; 5:717-22.
25. Vestergaard M, Hviid A, Madsen K, Wohlfahrt J, Thorsen P, Schendel D, Melbye M, Olsen J. MMR vaccination and febrile seizures: Evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292: 351-7.
26. Costa W, Sacchi C, Ramos S, Milagres L, Prigenzi L. Meningococcal disease in Sao Paulo, Brazil. NIPH Ann 1991; 14:215-8.
27. Center for Infectious Disease Prevention and Control. Canadian Immunization Guide. 6th ed. Ottawa: Canadian Medical Association, 2002.
28. National Health and Medical Research Council. The Australian Immunization Handbook. 7th ed. Canberra: The Australian Government Department of Health and Ageing, 2000.
29. World Health Organization Regional Office for the Western Pacific. Immunization safety surveillance: Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila: World Health Organization, 1999.
30. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, Jefferson T, Loupi E. The Brighton Collaboration: Addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002; 21:298-302.
31. Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, Rush M, Miller E. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345:567-9.
32. Cody C, Baraff L, Cherry J, Marcy S, Manclark C. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68:650-60.
33. Jackson L, Carste B, Malais D, Froeschle J. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J 2002; 21:781-5.
34. Le Saux N, Barrowman N, Moore D, Whiting S, Scheifele D, Halperin S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: A report from IMPACT. Pediatrics 2003; 112:e348-53.
35. Miller E, Waight P, Farrington P, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227-9.
36. Black C, Kaye J, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Gin Pharmacol 2003; 55:107-11.
37. Jadavji T, Scheifele D, Halperin S. Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatr Infect Dis J 2002; 22:119-22.
38. Chen R. Evaluation of vaccine safety after the events of 11 September 2001: Role of cohort and case-control studies. Vaccine 2004; 22:2047-53.
39. Walker A, Hershel J, Perera D, Knauss T, Thompson R. Neurological events following diphtheria-tetanus-pertussis immunization. Pediatrics 1988; 81:345-9.
40. Griffin M, Ray W, Mortimer E, Fenichel G, Schaffner W. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA 1990; 263:1641-5.
41. Gale G, Thapa P, Wassilak S, Bobo J, Mendelman P, Foy H. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. JAMA 1994; 271:37-41.
42. Waruiru C, Appleton R. Febrile seizures: An update. Arch Dis Child 2004; 89:751-6.
43. Gardner-Medwin J, Dolezalova P, Cummins C, Southwood T. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360:1197-202.
44. Mills J, Michel B, Bloch D, Calabrese L, Hunder G, Arend W, Edworthy S, Fauci A, Leavitt R, Lie J, Lightfoot R, Masi A, McShane D, Stevens M, Wallace S, Zvaifler N. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthriris Rheum 1990; 33:1114-21.
45. Courtney P, Patterson R, Lee R. Henoch-Schönlein purpura following meningitis C vaccination. Rheumatology 2001; 40:345-6.
46. Mormile R, D'Alterio V, Treccagnoli G, Sorrentino P. Henoch- Schönlein purpura with antiphospholipid antibodies after influenza vaccination: How fearful is it in children? Vaccine 2004; 23:567-8.
47. Watanabe T, Onda H. Henoch-Schönlein purpura with antiphospholipid antibodies following an influenza vaccination. Pediatr Nephrol 2001; 16:458-9.
48. Lambert E, Liebling A, Glusac E, Antaya R. Henoch-Schönlein purpura following a meningococcal vaccine. Pediatrics 2003; 112:e491-4.
49. Ozaki T, Miwata H, Kodama H, Matsui Y, Asano Y. Henoch-Schönlein purpura after measles immunization. Acta Paediatr Jpn 1989; 31:484-6.
50. Patel U, Bradley J, Hamilton D. Henoch-Schönlein Purpura after influenza vaccination. BMJ 1988; 296:1800.
51. Chave T, Neal C, Camp R. Henoch-Schönlein purpura following hepatitis B vaccination. J Dermatol Treat 2003; 14:179-81.
52. Francois G, Duclos P, Margolis H, Lavanchy D, Siegrist C, Meheus A, Lambert P, Emiroglu N, Badur S, Van Damme P. Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J 2005; 24:953-61.
53. Duclos P. A global perspective on vaccine safety. Vaccine 2004; 22:2059-63.
54. Maldonado Y. Current controversies in vaccination. Vaccine Saftety. JAMA 2002; 288:3155-8.
55. Lennon D, Gellin B, Hood D, Leach D, Woods G, Williams P, Thakur S, Crombie D. Control of epidemic group A meningococcal disease in Auckland. N Z Med J 1993; 106:3-6.
56. CBG. Audit of MeNZB™ data in the National Immunisation Register. Round 2. Accuracy and completeness up to March 2005. Prepared for the Ministry of Health. CBG Health Research Limited, May 2005.
57. Chen RT. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley and Sons, 2000:707-32.
58. Jacobson R, Adegbenro A, Pankratz S, Poland G. Adverse events and vaccination - the lack of power and predicatability of infrequent events in pre-licensure study. Vaccine 2001; 19:2428-33.
59. Ellenberg S, Foulkes M, Midthun K, Goldenthal K. Evaluating the safety of new vaccines: Summary of a workshop. Am J Public Health 2005; 95:800-7.